Staging and reporting of cancers of the urinary tract have undergone major changes in the past decade to meet the needs for improved patient management. Substantial progress has been made. There, however, remain issues that require further clarity, including the substaging of pT1 tumors, grading and reporting of tumors with grade heterogeneity, and following NAC. Multi-institutional collaborative studies with prospective data will further inform the accurate diagnosis, staging, and reporting of these tumors, and in conjunction with genomic data will ultimately contribute to precision and personalized patient management.
Keywords: AJCC staging; Bladder; Grading; Neoadjuvant chemotherapy; Pathologic staging; Reporting; Urinary tract; Urothelial carcinoma.
Copyright © 2022 Elsevier Inc. All rights reserved.